In the early days of May, we celebrate Labour and Spring

Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489932 [uid] => 2032 [title] => In the early days of May, we celebrate Labour and Spring [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118303 [type] => box_lancio_news [language] => it [created] => 1745843420 [changed] => 1745843666 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745843666 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[summary] => [format] => 2 [safe_value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139217 [uid] => 2032 [filename] => n_primavera_pesco_1.jpg [uri] => public://n_primavera_pesco_1_0.jpg [filemime] => image/jpeg [filesize] => 18479 [status] => 1 [timestamp] => 1745843420 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => peache [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May [format] => [safe_value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/maggio25 [format] => [safe_value] => https://www.unipd.it/news/maggio25 ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 489932 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[summary] => [format] => 2 [safe_value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489932 [uid] => 2032 [title] => In the early days of May, we celebrate Labour and Spring [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118303 [type] => box_lancio_news [language] => it [created] => 1745843420 [changed] => 1745843666 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745843666 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[summary] => [format] => 2 [safe_value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139217 [uid] => 2032 [filename] => n_primavera_pesco_1.jpg [uri] => public://n_primavera_pesco_1_0.jpg [filemime] => image/jpeg [filesize] => 18479 [status] => 1 [timestamp] => 1745843420 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => peache [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May [format] => [safe_value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/maggio25 [format] => [safe_value] => https://www.unipd.it/news/maggio25 ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 489932 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 139217 [uid] => 2032 [filename] => n_primavera_pesco_1.jpg [uri] => public://n_primavera_pesco_1_0.jpg [filemime] => image/jpeg [filesize] => 18479 [status] => 1 [timestamp] => 1745843420 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => peache [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 139217 [uid] => 2032 [filename] => n_primavera_pesco_1.jpg [uri] => public://n_primavera_pesco_1_0.jpg [filemime] => image/jpeg [filesize] => 18479 [status] => 1 [timestamp] => 1745843420 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => peache [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489932 [uid] => 2032 [title] => In the early days of May, we celebrate Labour and Spring [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118303 [type] => box_lancio_news [language] => it [created] => 1745843420 [changed] => 1745843666 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745843666 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[summary] => [format] => 2 [safe_value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139217 [uid] => 2032 [filename] => n_primavera_pesco_1.jpg [uri] => public://n_primavera_pesco_1_0.jpg [filemime] => image/jpeg [filesize] => 18479 [status] => 1 [timestamp] => 1745843420 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => peache [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May [format] => [safe_value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/maggio25 [format] => [safe_value] => https://www.unipd.it/news/maggio25 ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 489932 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May [format] => [safe_value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May ) ) [#formatter] => text_default [0] => Array ( [#markup] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about In the early days of May, we celebrate Labour and Spring [href] => node/118303 [html] => 1 [attributes] => Array ( [rel] => tag [title] => In the early days of May, we celebrate Labour and Spring ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489932 [uid] => 2032 [title] => In the early days of May, we celebrate Labour and Spring [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118303 [type] => box_lancio_news [language] => it [created] => 1745843420 [changed] => 1745843666 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745843666 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[summary] => [format] => 2 [safe_value] =>

Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May.

During these days, the University's Botanical Garden will be open and will host the Spring Festival "Risvegli, the Flower Festival," four days of shows, meetings, exhibitions, guided tours, and workshops for all ages, in a rich program that spans scientific dissemination and artistic entertainment. An inexhaustible source of knowledge, inspiration for art and literature, and a natural resource, flowers and plants are the protagonists of an authentic garden of wonders, suspended between fragrances and colours. It will be a multisensory journey with activities suitable for everyone, celebrating Nature and culture. Additionally, from 1st to 4th May, for the festival, the Botanical Garden will be exceptionally open from 9 AM to 7 PM.

The Botanical Museum will also offer a special initiative from 2 to 4 May: "Flowers of the Sea. The Beauty of Algae," guided tours of the thematic exhibition in the Museum's Consultation Room.

On Saturday, 3 May, as on every first Saturday of the month, the "Saturday at Liviano" initiative will continue: an integrated tour that includes visits to the atrium of Palazzo Liviano, the Hall of Giants, and the Museum of Archaeological Sciences and Art, available every first Saturday of the month.

Palazzo Bo will be open for guided tours, with a special tour on "The 1900s of Gio Ponti," which includes, in addition to the spaces of the "Historical Tour," the Rectorate, the Ancient Archive, and the Basilica.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139217 [uid] => 2032 [filename] => n_primavera_pesco_1.jpg [uri] => public://n_primavera_pesco_1_0.jpg [filemime] => image/jpeg [filesize] => 18479 [status] => 1 [timestamp] => 1745843420 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => peache [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May [format] => [safe_value] => Educational activities are suspended on Thursday, 1st May, a national holiday for Labour Day, and Friday, 2nd May 2025, the date when this year the Justinian feast is celebrated. Several study rooms will remain open, even on days when classes are suspended. Unipd offices will be closed from 1 to 4 May ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/maggio25 [format] => [safe_value] => https://www.unipd.it/news/maggio25 ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 489932 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Lun, 28/04/2025 ) ) )

Chronic Lymphocytic Leukaemia: study demonstrates the effectiveness of biological therapies in elderly patients

Array ( [field_link_esterno_news] => Array ( [#theme] => field [#weight] => -1 [#title] => Link esterno news [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_link_esterno_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489927 [uid] => 2032 [title] => Chronic Lymphocytic Leukaemia: study demonstrates the effectiveness of biological therapies in elderly patients [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118302 [type] => box_lancio_news [language] => it [created] => 1745842616 [changed] => 1745842616 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842616 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[summary] => [format] => 2 [safe_value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139216 [uid] => 2032 [filename] => n_leucemia_1.jpg [uri] => public://n_leucemia_1_0.jpg [filemime] => image/jpeg [filesize] => 23746 [status] => 1 [timestamp] => 1745842616 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => leukemia [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients [format] => [safe_value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani [format] => [safe_value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 489927 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489927 [uid] => 2032 [title] => Chronic Lymphocytic Leukaemia: study demonstrates the effectiveness of biological therapies in elderly patients [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118302 [type] => box_lancio_news [language] => it [created] => 1745842616 [changed] => 1745842616 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842616 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[summary] => [format] => 2 [safe_value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139216 [uid] => 2032 [filename] => n_leucemia_1.jpg [uri] => public://n_leucemia_1_0.jpg [filemime] => image/jpeg [filesize] => 23746 [status] => 1 [timestamp] => 1745842616 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => leukemia [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients [format] => [safe_value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani [format] => [safe_value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 489927 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[summary] => [format] => 2 [safe_value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489927 [uid] => 2032 [title] => Chronic Lymphocytic Leukaemia: study demonstrates the effectiveness of biological therapies in elderly patients [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118302 [type] => box_lancio_news [language] => it [created] => 1745842616 [changed] => 1745842616 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842616 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[summary] => [format] => 2 [safe_value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139216 [uid] => 2032 [filename] => n_leucemia_1.jpg [uri] => public://n_leucemia_1_0.jpg [filemime] => image/jpeg [filesize] => 23746 [status] => 1 [timestamp] => 1745842616 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => leukemia [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients [format] => [safe_value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani [format] => [safe_value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 489927 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 139216 [uid] => 2032 [filename] => n_leucemia_1.jpg [uri] => public://n_leucemia_1_0.jpg [filemime] => image/jpeg [filesize] => 23746 [status] => 1 [timestamp] => 1745842616 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => leukemia [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 139216 [uid] => 2032 [filename] => n_leucemia_1.jpg [uri] => public://n_leucemia_1_0.jpg [filemime] => image/jpeg [filesize] => 23746 [status] => 1 [timestamp] => 1745842616 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => leukemia [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489927 [uid] => 2032 [title] => Chronic Lymphocytic Leukaemia: study demonstrates the effectiveness of biological therapies in elderly patients [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118302 [type] => box_lancio_news [language] => it [created] => 1745842616 [changed] => 1745842616 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842616 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[summary] => [format] => 2 [safe_value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139216 [uid] => 2032 [filename] => n_leucemia_1.jpg [uri] => public://n_leucemia_1_0.jpg [filemime] => image/jpeg [filesize] => 23746 [status] => 1 [timestamp] => 1745842616 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => leukemia [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients [format] => [safe_value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani [format] => [safe_value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 489927 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients [format] => [safe_value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients ) ) [#formatter] => text_default [0] => Array ( [#markup] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Chronic Lymphocytic Leukaemia: study demonstrates the effectiveness of biological therapies in elderly patients [href] => node/118302 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Chronic Lymphocytic Leukaemia: study demonstrates the effectiveness of biological therapies in elderly patients ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489927 [uid] => 2032 [title] => Chronic Lymphocytic Leukaemia: study demonstrates the effectiveness of biological therapies in elderly patients [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118302 [type] => box_lancio_news [language] => it [created] => 1745842616 [changed] => 1745842616 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842616 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[summary] => [format] => 2 [safe_value] =>

A research team led by the University of Padua coordinated a key study on targeted therapies for the treatment of chronic lymphocytic leukaemia, a rare cancer that represents the most frequent type of leukaemia affecting the western population. One-third of patients diagnosed with this disease are over 80 years old, and the treatment and management of this patient group is a challenge for medicine due to their fragility and exclusion from clinical trials.

In the study "Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort," published in the prestigious journal "Blood" and coordinated by Andrea Visentin from the Department of Medicine at the University of Padua, in collaboration with Massimo Gentile from the Hematology Unit of Cosenza, data from over 120 patients from 23 institutions across the country were collected, managing to analyse the largest group of patients over 80 treated with venetoclax. "Venetoclax is an anti-cancer compound administered in tablets that targets BCL2, a protein altered in chronic lymphocytic leukaemia, and when targeted, leads to the death of leukaemia cells," explains Prof. Livio Trentin, Chair of Hematology at the University of Padua and Director of the Hematology Unit at the Padua University Hospital.

"The key to this study was the personalisation of therapy," explains Andrea Visentin, coordinator of the study. "Reducing the drug dosage or reaching the full dose more slowly allowed us to limit the side effects of the therapy while ensuring its effectiveness. Today, we have many active biological drugs against tumours; balancing efficacy and side effects is the great challenge we will face in the coming years."

"It is interesting to note," says Trentin, "that the first authors of this study on patients aged 80-94 are young researchers: a research fellow, Alessandro Cellini, and a specialist trainee, Andrea Serafin. Additionally, these studies hold social importance because they were carried out thanks to the involvement and contribution of the volunteer association 'Ricerca per Credere nella Vita' (RCV), an association created by one of our patients, Franca Boschello, and her brother Renzo, which has supported the facility where we operate for about 20 years."

The chronic lymphocytic leukaemia research team at the Hematology Unit of the Padua University Hospital has presented projects and conducted international relations, confirming itself as one of the European reference centres for this disease.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139216 [uid] => 2032 [filename] => n_leucemia_1.jpg [uri] => public://n_leucemia_1_0.jpg [filemime] => image/jpeg [filesize] => 23746 [status] => 1 [timestamp] => 1745842616 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => leukemia [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients [format] => [safe_value] => Chronic Lymphocytic Leukaemia: Italian study coordinated by the University of Padua demonstrates the effectiveness of biological therapies in elderly patients ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani [format] => [safe_value] => https://www.unipd.it/news/leucemia-linfatica-cronica-studio-dimostra-efficacia-terapie-biologiche-nei-pazienti-anziani ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 489927 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Lun, 28/04/2025 ) ) )

Leucemia linfatica cronica: studio dimostra l’efficacia delle terapie biologiche nei pazienti anziani

Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489928 [uid] => 2032 [title] => Leucemia linfatica cronica: studio dimostra l’efficacia delle terapie biologiche nei pazienti anziani [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118301 [type] => box_lancio_news [language] => it [created] => 1745842358 [changed] => 1745842639 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842639 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[summary] => [format] => 2 [safe_value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139215 [uid] => 2032 [filename] => n_leucemia.jpg [uri] => public://n_leucemia_1.jpg [filemime] => image/jpeg [filesize] => 95255 [status] => 1 [timestamp] => 1745842358 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => leucemia [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani [format] => [safe_value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) [1] => Array ( [tid] => 2267 ) [2] => Array ( [tid] => 2462 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => /news/chronic-lymphocytic-leukaemia-study-demonstrates-effectiveness-biological-therapies-elderly [format] => [safe_value] => /news/chronic-lymphocytic-leukaemia-study-demonstrates-effectiveness-biological-therapies-elderly ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => English version [format] => [safe_value] => English version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 489928 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[summary] => [format] => 2 [safe_value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489928 [uid] => 2032 [title] => Leucemia linfatica cronica: studio dimostra l’efficacia delle terapie biologiche nei pazienti anziani [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118301 [type] => box_lancio_news [language] => it [created] => 1745842358 [changed] => 1745842639 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842639 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[summary] => [format] => 2 [safe_value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139215 [uid] => 2032 [filename] => n_leucemia.jpg [uri] => public://n_leucemia_1.jpg [filemime] => image/jpeg [filesize] => 95255 [status] => 1 [timestamp] => 1745842358 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => leucemia [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani [format] => [safe_value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) [1] => Array ( [tid] => 2267 ) [2] => Array ( [tid] => 2462 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => /news/chronic-lymphocytic-leukaemia-study-demonstrates-effectiveness-biological-therapies-elderly [format] => [safe_value] => /news/chronic-lymphocytic-leukaemia-study-demonstrates-effectiveness-biological-therapies-elderly ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => English version [format] => [safe_value] => English version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 489928 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 139215 [uid] => 2032 [filename] => n_leucemia.jpg [uri] => public://n_leucemia_1.jpg [filemime] => image/jpeg [filesize] => 95255 [status] => 1 [timestamp] => 1745842358 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => leucemia [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 139215 [uid] => 2032 [filename] => n_leucemia.jpg [uri] => public://n_leucemia_1.jpg [filemime] => image/jpeg [filesize] => 95255 [status] => 1 [timestamp] => 1745842358 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => leucemia [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489928 [uid] => 2032 [title] => Leucemia linfatica cronica: studio dimostra l’efficacia delle terapie biologiche nei pazienti anziani [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118301 [type] => box_lancio_news [language] => it [created] => 1745842358 [changed] => 1745842639 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842639 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[summary] => [format] => 2 [safe_value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139215 [uid] => 2032 [filename] => n_leucemia.jpg [uri] => public://n_leucemia_1.jpg [filemime] => image/jpeg [filesize] => 95255 [status] => 1 [timestamp] => 1745842358 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => leucemia [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani [format] => [safe_value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) [1] => Array ( [tid] => 2267 ) [2] => Array ( [tid] => 2462 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => /news/chronic-lymphocytic-leukaemia-study-demonstrates-effectiveness-biological-therapies-elderly [format] => [safe_value] => /news/chronic-lymphocytic-leukaemia-study-demonstrates-effectiveness-biological-therapies-elderly ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => English version [format] => [safe_value] => English version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 489928 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani [format] => [safe_value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani ) ) [#formatter] => text_default [0] => Array ( [#markup] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Leucemia linfatica cronica: studio dimostra l’efficacia delle terapie biologiche nei pazienti anziani [href] => node/118301 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Leucemia linfatica cronica: studio dimostra l’efficacia delle terapie biologiche nei pazienti anziani ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 489928 [uid] => 2032 [title] => Leucemia linfatica cronica: studio dimostra l’efficacia delle terapie biologiche nei pazienti anziani [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118301 [type] => box_lancio_news [language] => it [created] => 1745842358 [changed] => 1745842639 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842639 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[summary] => [format] => 2 [safe_value] =>

Team di ricerca guidato dall’Università di Padova ha coordinato uno studio chiave sulle terapie mirate per la cura della leucemia linfatica cronica, tumore raro che rappresenta il tipo più frequente di leucemia che colpisce la popolazione occidentale. Un terzo dei pazienti che si ammala di questa malattia ha più di 80 anni e il trattamento e la gestione di questo gruppo di pazienti rappresenta una sfida per la medicina data la fragilità dei pazienti e l’esclusione dagli studi clinici.

Nello studio Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort, pubblicato sulla prestigiosa rivista «Blood» e coordinato da Andrea Visentin del Dipartimento di Medicina dell’Università di Padova, in collaborazione con Massimo Gentile della UOC di Ematologia di Cosenza, sono stati raccolti i dati di più di 120 pazienti da 23 istituti sparsi sul territorio nazionale, riuscendo ad analizzare il più grande gruppo di pazienti con più di 80 anni trattato con venetoclax. «Venetoclax è un principio attivo antitumorale somministrato in compresse che colpisce BCL2, una proteina alterata nella leucemia linfatica cronica e che, quando colpita, porta a morte le cellule della leucemia.» spiega il prof Livio Trentin, ordinario della cattedra di ematologia dell’Università di Padova e direttore della UOC di Ematologia dell’Azienda Ospedale Università di Padova.

«La chiave di questo studio è stata la personalizzazione della terapia – spiega Andrea Visentin coordinatore dello studio -. La riduzione del dosaggio del farmaco o il raggiungimento più lento della dose piena del farmaco ha permesso di limitare gli effetti collaterali della terapia garantendo contestualmente l’efficacia della stessa. Oggi abbiamo a disposizione molti farmaci biologici attivi nei confronti dei tumori; riuscire a bilanciare efficacia ed effetti collaterali è la grande sfida che dovremo affrontare nei prossimi anni».

«Interessante notare - dice Trentin -, come i primi autori di questo studio sui pazienti tra 80-94 anni siano dei giovani ricercatori: un assegnista di ricerca, Alessandro Cellini, ed uno specializzando,  Andrea Serafin. Inoltre, questi studi ricoprono un’importanza sociale perché realizzate grazie al coinvolgimento e al contributo dell’associazione di volontariato Ricerca per Credere nella vita (RCV), associazione creata da una nostra paziente, Franca Boschello e suo fratello Renzo, e che supporta la struttura in cui operiamo da circa 20 anni.»

Il team di ricerca sulla leucemia linfatica cronica dell’Ematologia dell’Azienda Ospedale - Università Padova ha presentato progetti e svolto relazioni internazionali, confermandosi uno dei centri di riferimento europeo per questa malattia.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 139215 [uid] => 2032 [filename] => n_leucemia.jpg [uri] => public://n_leucemia_1.jpg [filemime] => image/jpeg [filesize] => 95255 [status] => 1 [timestamp] => 1745842358 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => leucemia [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani [format] => [safe_value] => Leucemia linfatica cronica: studio italiano coordinato dall’Università di Padova dimostra l’efficacia delle terapie biologiche nei pazienti anziani ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) [1] => Array ( [tid] => 2267 ) [2] => Array ( [tid] => 2462 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [value2] => 2026-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => /news/chronic-lymphocytic-leukaemia-study-demonstrates-effectiveness-biological-therapies-elderly [format] => [safe_value] => /news/chronic-lymphocytic-leukaemia-study-demonstrates-effectiveness-biological-therapies-elderly ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => English version [format] => [safe_value] => English version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 489928 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2025-04-28T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Lun, 28/04/2025 ) ) )

2025N15 - Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i. (pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025)

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 489924 [uid] => 32 [title] => 2025N15 - Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i. (pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118300 [type] => allegato [language] => it [created] => 1745842300 [changed] => 1745842300 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842300 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i.
(pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) [format] => [safe_value] => Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i.<br>(pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 139214 [uid] => 32 [filename] => 7. Mob.Obbligatoria_2025N15.pdf [uri] => public://2025/7. Mob.Obbligatoria_2025N15.pdf [filemime] => application/pdf [filesize] => 171062 [status] => 1 [timestamp] => 1745842296 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489924 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i.
(pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) [format] => [safe_value] => Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i.<br>(pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) ) ) [#formatter] => text_default [0] => Array ( [#markup] => Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i.<br>(pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 489924 [uid] => 32 [title] => 2025N15 - Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i. (pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118300 [type] => allegato [language] => it [created] => 1745842300 [changed] => 1745842300 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745842300 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i.
(pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) [format] => [safe_value] => Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i.<br>(pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 139214 [uid] => 32 [filename] => 7. Mob.Obbligatoria_2025N15.pdf [uri] => public://2025/7. Mob.Obbligatoria_2025N15.pdf [filemime] => application/pdf [filesize] => 171062 [status] => 1 [timestamp] => 1745842296 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489924 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 139214 [uid] => 32 [filename] => 7. Mob.Obbligatoria_2025N15.pdf [uri] => public://2025/7. Mob.Obbligatoria_2025N15.pdf [filemime] => application/pdf [filesize] => 171062 [status] => 1 [timestamp] => 1745842296 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 139214 [uid] => 32 [filename] => 7. Mob.Obbligatoria_2025N15.pdf [uri] => public://2025/7. Mob.Obbligatoria_2025N15.pdf [filemime] => application/pdf [filesize] => 171062 [status] => 1 [timestamp] => 1745842296 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2025N15 - Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i. (pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) [href] => node/118300 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2025N15 - Esito procedura di mobilità obbligatoria ex art. 34-bis del D.Lgs 165/2001 s.m.i. (pubblicato all'Albo Ufficiale di Ateneo in data 28/04/2025) ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Bando - Premio Michele Malanca - Scadenza 28-02-2026

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 489910 [uid] => 32 [title] => Bando - Premio Michele Malanca - Scadenza 28-02-2026 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118299 [type] => allegato [language] => it [created] => 1745837136 [changed] => 1745837136 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745837136 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Bando [format] => [safe_value] => Bando ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 139212 [uid] => 32 [filename] => bando Michele Malanca 2025.pdf [uri] => public://2025/bando Michele Malanca 2025.pdf [filemime] => application/pdf [filesize] => 283443 [status] => 1 [timestamp] => 1745837129 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489910 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Bando [format] => [safe_value] => Bando ) ) [#formatter] => text_default [0] => Array ( [#markup] => Bando ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 489910 [uid] => 32 [title] => Bando - Premio Michele Malanca - Scadenza 28-02-2026 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118299 [type] => allegato [language] => it [created] => 1745837136 [changed] => 1745837136 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745837136 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Bando [format] => [safe_value] => Bando ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 139212 [uid] => 32 [filename] => bando Michele Malanca 2025.pdf [uri] => public://2025/bando Michele Malanca 2025.pdf [filemime] => application/pdf [filesize] => 283443 [status] => 1 [timestamp] => 1745837129 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489910 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 139212 [uid] => 32 [filename] => bando Michele Malanca 2025.pdf [uri] => public://2025/bando Michele Malanca 2025.pdf [filemime] => application/pdf [filesize] => 283443 [status] => 1 [timestamp] => 1745837129 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 139212 [uid] => 32 [filename] => bando Michele Malanca 2025.pdf [uri] => public://2025/bando Michele Malanca 2025.pdf [filemime] => application/pdf [filesize] => 283443 [status] => 1 [timestamp] => 1745837129 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Bando - Premio Michele Malanca - Scadenza 28-02-2026 [href] => node/118299 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Bando - Premio Michele Malanca - Scadenza 28-02-2026 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Calendario accademico anno 2025/2026

Array ( [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 489903 [uid] => 13 [title] => Calendario accademico anno 2025/2026 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118298 [type] => allegato [language] => it [created] => 1745836239 [changed] => 1748258282 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1748258282 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 140131 [uid] => 32 [filename] => Calendario accademico 2025-26_ITA.pdf [uri] => public://2025/Calendario accademico 2025-26_ITA.pdf [filemime] => application/pdf [filesize] => 205772 [status] => 1 [timestamp] => 1748258278 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => chiara.mezzalira [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-e496b743db3766e42eb8a4d1ccc1c014";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489903 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 140131 [uid] => 32 [filename] => Calendario accademico 2025-26_ITA.pdf [uri] => public://2025/Calendario accademico 2025-26_ITA.pdf [filemime] => application/pdf [filesize] => 205772 [status] => 1 [timestamp] => 1748258278 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 140131 [uid] => 32 [filename] => Calendario accademico 2025-26_ITA.pdf [uri] => public://2025/Calendario accademico 2025-26_ITA.pdf [filemime] => application/pdf [filesize] => 205772 [status] => 1 [timestamp] => 1748258278 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Calendario accademico anno 2025/2026 [href] => node/118298 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Calendario accademico anno 2025/2026 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

GEMONT Iscrizione e informazioni generali

Array ( [field_accordion_sottotitolo] => Array ( [#theme] => field [#weight] => -3 [#title] => Sotto titolo [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_accordion_sottotitolo [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => accordion [#object] => stdClass Object ( [vid] => 489883 [uid] => 4 [title] => GEMONT Iscrizione e informazioni generali [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118297 [type] => accordion [language] => it [created] => 1745834639 [changed] => 1745834639 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745834639 [revision_uid] => 4 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) ) [field_accordion_element] => Array ( ) [field_accordion_sottotitolo] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_accordion_titolo_fro] => Array ( ) [field_allegato_element] => Array ( ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489883 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => -2 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => accordion [#object] => stdClass Object ( [vid] => 489883 [uid] => 4 [title] => GEMONT Iscrizione e informazioni generali [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118297 [type] => accordion [language] => it [created] => 1745834639 [changed] => 1745834639 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745834639 [revision_uid] => 4 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) ) [field_accordion_element] => Array ( ) [field_accordion_sottotitolo] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_accordion_titolo_fro] => Array ( ) [field_allegato_element] => Array ( ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489883 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about GEMONT Iscrizione e informazioni generali [href] => node/118297 [html] => 1 [attributes] => Array ( [rel] => tag [title] => GEMONT Iscrizione e informazioni generali ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

COMMON Iscrizione e informazioni generali

Array ( [field_accordion_sottotitolo] => Array ( [#theme] => field [#weight] => -3 [#title] => Sotto titolo [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_accordion_sottotitolo [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => accordion [#object] => stdClass Object ( [vid] => 489881 [uid] => 4 [title] => COMMON Iscrizione e informazioni generali [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118296 [type] => accordion [language] => it [created] => 1745834567 [changed] => 1745834567 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745834567 [revision_uid] => 4 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) ) [field_accordion_element] => Array ( ) [field_accordion_sottotitolo] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_accordion_titolo_fro] => Array ( ) [field_allegato_element] => Array ( ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489881 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => -2 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => accordion [#object] => stdClass Object ( [vid] => 489881 [uid] => 4 [title] => COMMON Iscrizione e informazioni generali [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118296 [type] => accordion [language] => it [created] => 1745834567 [changed] => 1745834567 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745834567 [revision_uid] => 4 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) ) [field_accordion_element] => Array ( ) [field_accordion_sottotitolo] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_accordion_titolo_fro] => Array ( ) [field_allegato_element] => Array ( ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489881 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about COMMON Iscrizione e informazioni generali [href] => node/118296 [html] => 1 [attributes] => Array ( [rel] => tag [title] => COMMON Iscrizione e informazioni generali ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

NEWMONT Iscrizione e informazioni generali

Array ( [field_accordion_sottotitolo] => Array ( [#theme] => field [#weight] => -3 [#title] => Sotto titolo [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_accordion_sottotitolo [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => accordion [#object] => stdClass Object ( [vid] => 489879 [uid] => 4 [title] => NEWMONT Iscrizione e informazioni generali [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118295 [type] => accordion [language] => it [created] => 1745834493 [changed] => 1745834493 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745834493 [revision_uid] => 4 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) ) [field_accordion_element] => Array ( ) [field_accordion_sottotitolo] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_accordion_titolo_fro] => Array ( ) [field_allegato_element] => Array ( ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489879 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => -2 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => accordion [#object] => stdClass Object ( [vid] => 489879 [uid] => 4 [title] => NEWMONT Iscrizione e informazioni generali [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118295 [type] => accordion [language] => it [created] => 1745834493 [changed] => 1745834493 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745834493 [revision_uid] => 4 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) ) [field_accordion_element] => Array ( ) [field_accordion_sottotitolo] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_accordion_titolo_fro] => Array ( ) [field_allegato_element] => Array ( ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489879 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about NEWMONT Iscrizione e informazioni generali [href] => node/118295 [html] => 1 [attributes] => Array ( [rel] => tag [title] => NEWMONT Iscrizione e informazioni generali ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

RIMONT Iscrizione e informazioni generali

Array ( [field_accordion_sottotitolo] => Array ( [#theme] => field [#weight] => -3 [#title] => Sotto titolo [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_accordion_sottotitolo [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => accordion [#object] => stdClass Object ( [vid] => 489877 [uid] => 4 [title] => RIMONT Iscrizione e informazioni generali [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118294 [type] => accordion [language] => it [created] => 1745834417 [changed] => 1745834417 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745834417 [revision_uid] => 4 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) ) [field_accordion_element] => Array ( ) [field_accordion_sottotitolo] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_accordion_titolo_fro] => Array ( ) [field_allegato_element] => Array ( ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489877 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => -2 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => accordion [#object] => stdClass Object ( [vid] => 489877 [uid] => 4 [title] => RIMONT Iscrizione e informazioni generali [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 118294 [type] => accordion [language] => it [created] => 1745834417 [changed] => 1745834417 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1745834417 [revision_uid] => 4 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) ) [field_accordion_element] => Array ( ) [field_accordion_sottotitolo] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_accordion_titolo_fro] => Array ( ) [field_allegato_element] => Array ( ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 489877 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[summary] => [format] => 2 [safe_value] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Linea rossa
freccia rossaIscrizione e informazioni generaliLinea rossa

) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about RIMONT Iscrizione e informazioni generali [href] => node/118294 [html] => 1 [attributes] => Array ( [rel] => tag [title] => RIMONT Iscrizione e informazioni generali ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Pagine